Johnson Financial Group Inc. Trims Stock Position in Pfizer Inc. (NYSE:PFE)

Johnson Financial Group Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 9.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 157,889 shares of the biopharmaceutical company’s stock after selling 17,336 shares during the period. Pfizer accounts for about 0.7% of Johnson Financial Group Inc.’s holdings, making the stock its 26th biggest position. Johnson Financial Group Inc.’s holdings in Pfizer were worth $6,892,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in PFE. Donaldson Capital Management LLC boosted its holdings in Pfizer by 2.9% during the third quarter. Donaldson Capital Management LLC now owns 740,284 shares of the biopharmaceutical company’s stock valued at $32,624,000 after acquiring an additional 20,611 shares during the period. Dixon Hubard Feinour & Brown Inc. VA boosted its holdings in Pfizer by 1.2% during the third quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 141,865 shares of the biopharmaceutical company’s stock valued at $6,252,000 after acquiring an additional 1,705 shares during the period. Bessemer Group Inc. boosted its holdings in Pfizer by 3,845.7% during the third quarter. Bessemer Group Inc. now owns 6,366,640 shares of the biopharmaceutical company’s stock valued at $280,580,000 after acquiring an additional 6,205,282 shares during the period. McKinley Carter Wealth Services Inc. bought a new stake in Pfizer during the third quarter valued at about $1,367,000. Finally, Fagan Associates Inc. bought a new stake in Pfizer during the third quarter valued at about $222,000. Institutional investors and hedge funds own 71.83% of the company’s stock.

In other news, insider Alexander R. Mackenzie sold 30,000 shares of the stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the completion of the sale, the insider now directly owns 80,094 shares in the company, valued at $3,524,136. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Pfizer Inc bought 50,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

A number of research firms have issued reports on PFE. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Goldman Sachs Group began coverage on shares of Pfizer in a report on Tuesday, May 28th. They set a “conviction-buy” rating for the company. Credit Suisse Group restated a “buy” rating and set a $48.00 price target on shares of Pfizer in a report on Monday, June 17th. Morgan Stanley started coverage on shares of Pfizer in a research note on Tuesday, June 4th. They issued an “overweight” rating and a $48.00 target price for the company. Finally, Barclays reiterated a “hold” rating and issued a $41.00 target price on shares of Pfizer in a research note on Thursday, May 9th. Thirteen equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $46.22.

Shares of NYSE PFE traded up $0.45 during mid-day trading on Monday, hitting $43.77. 20,234,126 shares of the stock were exchanged, compared to its average volume of 23,956,598. The firm has a market cap of $243.36 billion, a P/E ratio of 14.59, a P/E/G ratio of 2.51 and a beta of 0.64. Pfizer Inc. has a twelve month low of $36.00 and a twelve month high of $46.47. The firm’s fifty day moving average price is $42.48. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.10. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The firm had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same period in the previous year, the business earned $0.77 EPS. The company’s revenue was up 1.6% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.88 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be issued a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 3.29%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s dividend payout ratio is currently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: What is the Gross Domestic Product (GDP)?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.